Log in

Relevant bibliographies by topics / Human Parvovirus B19

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Human Parvovirus B19'

Author: Grafiati

Published: 4 June 2021

Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Human Parvovirus B19.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Human Parvovirus B19"

1

Qiu, Jianming, Maria Söderlund-Venermo, and Neal S. Young. "Human Parvoviruses." Clinical Microbiology Reviews 30, no. 1 (November 2, 2016): 43–113. http://dx.doi.org/10.1128/cmr.00040-16.

Full text

Abstract:

SUMMARY Parvovirus B19 (B19V) and human bocavirus 1 (HBoV1), members of the large Parvoviridae family, are human pathogens responsible for a variety of diseases. For B19V in particular, host features determine disease manifestations. These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results. Additional human parvoviruses, including HBoV2 to -4, human parvovirus 4 (PARV4), and human bufavirus (BuV) are also reviewed. The full spectrum of parvovirus disease in humans has yet to be established. Candidate recombinant B19V vaccines have been developed but may not be commercially feasible. We review relevant features of the molecular and cellular biology of these viruses, and the human immune response that they elicit, which have allowed a deep understanding of pathophysiology.

APA, Harvard, Vancouver, ISO, and other styles

2

Ussery, Xilla T., and Gail J. Demmler. "Human parvovirus B19." Seminars in Pediatric Infectious Diseases 7, no. 2 (April 1996): 89–96. http://dx.doi.org/10.1016/s1045-1870(96)81003-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Pattison, J. R. "Human parvovirus B19." BMJ 308, no. 6922 (January 15, 1994): 149–50. http://dx.doi.org/10.1136/bmj.308.6922.149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Igoe, D., B. Gilmer, H. Johnson, and H. J. O'Neill. "Human parvovirus B19." BMJ 308, no. 6933 (April 2, 1994): 918–19. http://dx.doi.org/10.1136/bmj.308.6933.918a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Heegaard, Erik D., and Kevin E. Brown. "Human Parvovirus B19." Clinical Microbiology Reviews 15, no. 3 (July 2002): 485–505. http://dx.doi.org/10.1128/cmr.15.3.485-505.2002.

Full text

Abstract:

SUMMARY Parvovirus B19 (B19) was discovered in 1974 and is the only member of the family Parvoviridae known to be pathogenic in humans. Despite the inability to propagate the virus in cell cultures, much has been learned about the pathophysiology of this virus, including the identification of the cellular receptor (P antigen), and the control of the virus by the immune system. B19 is widespread, and manifestations of infection vary with the immunologic and hematologic status of the host. In healthy immunocompetent individuals B19 is the cause of erythema infectiosum and, particularly in adults, acute symmetric polyarthropathy. Due to the tropism of B19 to erythroid progenitor cells, infection in individuals with an underlying hemolytic disorder causes transient aplastic crisis. In the immunocompromised host persistent B19 infection is manifested as pure red cell aplasia and chronic anemia. Likewise, the immature immune response of the fetus may render it susceptible to infection, leading to fetal death in utero, hydrops fetalis, or development of congenital anemia. B19 has also been suggested as the causative agent in a variety of clinical syndromes, but given the common nature, causality is often difficult to infer. Diagnosis is primarily based on detection of specific antibodies by enzyme-linked immunosorbent assay or detection of viral DNA by dot blot hybridization or PCR. Treatment of persistent infection with immunoglobulin reduces the viral load and results in a marked resolution of anemia. Vaccine phase I trials show promising results.

APA, Harvard, Vancouver, ISO, and other styles

6

Anderson, Larry J., and Thomas J. Török. "Human Parvovirus B19." New England Journal of Medicine 321, no. 8 (August 24, 1989): 536–38. http://dx.doi.org/10.1056/nejm198908243210809.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Anderson, Larry J. "Human Parvovirus B19." Pediatric Annals 19, no. 9 (September 1, 1990): 509–13. http://dx.doi.org/10.3928/0090-4481-19900901-06.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Milosevic, Vesna, Vera Jerant-Patic, Ivana Hrnjakovic-Cvjetkovic, Marija Vukmanovic-Papuga, Jelena Radovanov-Tadic, and Gordana Kovacevic. "The frequency of human parvovirus B19 infections in Vojvodina." Medical review 60, no. 11-12 (2007): 575–79. http://dx.doi.org/10.2298/mpns0712575m.

Full text

Abstract:

Introduction. Human parvovirus B19 is found worldwide. It causes various infections, including fifth disease (erythema infectiosum) in small children, acute arthropathy in adults, transient aplastic crisis and chronic anemia in immmunocompromised patients and even fetal infection, which may result in intrauterine fetal death or fetal hydrops. Many of these manifestations of B19 infection are caused by infection of erythroid precursor cells in bone marrow. Material and Methods. The aim of this paper was to establish the frequency of parvovirus B19 infection in the population of Vojvodina, as well as to indicate the significance of further investigations particularly in highly vulnerable population groups such as small children, pregnant women and immune deficient persons. A total of 244 serum samples of out- and in-patients of different age were analyzed using SERION ELISA classic parvovirus B19 IgG/IgM quantitative and qualitative tests for identification of specific antibodies against human parvovirus B19. Results. Acute infection was found in 35% of examinees, whereas parvoviurs B19 was identified in 32% of examined persons. Our tests results proved that 20% of examined pregnant women in our surroundings have acute HPB19 infection. At the same time, 45% of pregnant women have no specific antibodies, so they are at risk of infection during pregnancy. Acute infection was diagnosed in 41 children (43%): 22 samples (23%) were positive only to IgG antibodies and in 32 samples (34%) neither IgM nor IgG antibodies were identified. Acute infection was more frequently found in preschool children, i.e. in children aged 4 to 6 years (29%). Conclusion. In the absence of complete data on the frequency of particular diseases caused by this virus in our population, tests for human parvovirus B19 are strongly recommended.

APA, Harvard, Vancouver, ISO, and other styles

9

Weigel-Kelley, Kirsten A., Mervin C. Yoder, and Arun Srivastava. "α5β1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of β1 integrin for viral entry." Blood 102, no. 12 (December 1, 2003): 3927–33. http://dx.doi.org/10.1182/blood-2003-05-1522.

Full text

Abstract:

Abstract Replication of the pathogenic human parvovirus B19 is restricted to erythroid progenitor cells. Although blood group P antigen has been reported to be the cell surface receptor for parvovirus B19, a number of nonerythroid cells, which express P antigen, are not permissive for parvovirus B19 infection. We have documented that P antigen is necessary for parvovirus B19 binding but not sufficient for virus entry into cells. To test whether parvovirus B19 utilizes a cell surface coreceptor for entry, we used human erythroleukemia cells (K562), which allow parvovirus B19 binding but not entry. We report here that upon treatment with phorbol esters, K562 cells become adherent and permissive for parvovirus B19 entry, which is mediated by α5β1 integrins, but only in their high-affinity conformation. Mature human red blood cells (RBCs), which express high levels of P antigen, but not α5β1 integrins, bind parvovirus B19 but do not allow viral entry. In contrast, primary human erythroid progenitor cells express high levels of both P antigen and α5β1 integrins and allow β1 integrin–mediated entry of parvovirus B19. Thus, in a natural course of infection, RBCs are likely exploited for a highly efficient systemic dissemination of parvovirus B19.

APA, Harvard, Vancouver, ISO, and other styles

10

Carlsen, Karen Marie. "Human Parvovirus B19 Erythrovirus ." APMIS 114, s120 (August 2006): 1–121. http://dx.doi.org/10.1111/j.1600-0463.2006.apm_v114_s120.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Human Parvovirus B19"

1

Isa, Adiba. "Cellular immune responses against human parvovirus B19 infection /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-662-X/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Tolfvenstam, Thomas. "Human parvovirus B19 : studies on the pathogenesis of infection /." Stockholm, 2001. http://diss.kib.ki.se/2001/91-628-4710-4/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Norbeck, Oscar. "Clinical and immunological aspects of human parvovirus B19 infection /." Stockholm : Dept. of laboratory medicine, Karolinska institutet, 2005. http://diss.kib.ki.se/2005/91-7140-203-9/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Heegaard, Erik D. "Diagnostic and clinical aspects of human parvovirus B19 infection /." [S.l. : Erik D. Heegaard], 2003. http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&doc_number=010694314&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Blundell, Matthew Charles. "Characterization of the promoter in a human B19 parvovirus." Thesis, University of British Columbia, 1989. http://hdl.handle.net/2429/29011.

Full text

Abstract:

The nucleotide sequence of the B19-Wi isolate of an autonomous human parvovirus was determined and compared with the sequence of the closely related isolate, B19-Au. The B19-Wi genome was similar to the B19-Au genome, as shown from DNA sequence analyses. It had been previously suggested from the sequence of the B19-Au genome, that the termini may be imperfect inverted terminal repeats. The additional sequence present on the right-hand terminus of B19-Wi supported that supposition. The hairpin termini of the B19 genome were of the same type as those found in adeno-associated parvoviruses, and suggested B19 may be more closely related to AAV viruses than to the autonomous parvoviruses. In vitro transcription with HeLa nuclear extracts using B19-Wi DNA identified a single active RNA polymerase II promoter between map unit 5 and 6. A single promoter was unique; all other parvoviruses characterized to date have two or more active promoters. A series of ordered deletions, prepared in the region upstream of the initiation site of the promoter, indicated that multiple cis-activating motifs were required to maximize in vitro transcription. A transcription factor in HeLa cells specifically bound to and protected a GC rich sequence or GC-box upstream of the promoter, as shown by gel-shift competition assays, and DNAse I and DMS footprinting assays. The protected GC-box had the consensus sequence of a high affinity binding site for the trans-activating factor SP1. The GC-box also formed the distal element of a tandem SPl-like motif, 21 bp upstream of the active TATA box. Synthetic oligonucleotides containing the GC-box specifically bound a HeLa factor and also depressed in vitro transcription from the B19 promoter when added as a competitor. Although not conclusive, binding of the HeLa factor may be inhibited by methylation of a cytosine residue within the GC-box. In vitro transcriptional activity decreased when the GC-box upstream of the B19 promoter was modified by site specific mutagenesis. Preliminary identification of other cis-activating motifs, which include two sequences recognized by factors that are functional both in transcription and replication, suggested that the B19 promoter is a complex regulatory region.
Medicine, Faculty of
Biochemistry and Molecular Biology, Department of
Graduate

APA, Harvard, Vancouver, ISO, and other styles

6

Morey, Adrienne Louise. "The pathogenesis of parvovirus B19 infection in the human fetus." Thesis, University of Oxford, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.316848.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Carlsen, Karen Marie. "Human parvovirus B19 erythrovirus : methods established for virological and diagnostic aspects /." Copenhagen : Blackwell Munksgaard, 2006. http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&doc_number=014982739&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lundqvist, Anders. "Clinical and laboratory findings in patients with persistent parvovirus 19 infection /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-828-2/.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Sanchez, Jonathan L., Zachary Romero, Angelica Quinones, Kristiane R. Torgeson, and Nancy C. Horton. "DNA Binding and Cleavage by the Human Parvovirus B19 NS1 Nuclease Domain." AMER CHEMICAL SOC, 2016. http://hdl.handle.net/10150/622382.

Full text

Abstract:

Infection with human parvovirus B19 (B19V) has been associated with a myriad of illnesses, including erythema infectiosum (Fifth disease), hydrops fetalis, arthropathy, hepatitis, and cardiomyopathy, and also possibly the triggering of any number of different autoimmune diseases. B19V NS1 is a multidomain protein that plays a critical role in viral replication, with predicted nuclease, helicase, and gene transactivation activities. Herein, we investigate the biochemical activities of the nuclease domain (residues 2-176) of B19V NS1 (NS1-nuc) in sequence-specific DNA binding of the viral origin of replication sequences, as well as those of promoter sequences, including the viral p6 and the human p21, TNF alpha, and IL-6 promoters previously identified in NS1-dependent transcriptional transactivation. NS1-nuc was found to bind with high cooperativity and with multiple (five to seven) copies to the NS1 binding elements (NSBE) found in the viral origin of replication and the overlapping viral p6 promoter DNA sequence. NS1-nuc was also found to bind cooperatively with at least three copies to the GC-rich Spl binding sites of the human p21 gene promoter. Only weak or nonspecific binding of NS1-nuc to the segments of the TNF alpha and IL-6 promoters was found. Cleavage of DNA by NS1-nuc occurred at the expected viral sequence (the terminal resolution site), but only in single-stranded DNA, and NS1-nuc was found to covalently attach to the 5' end of the DNA at the cleavage site. Off-target cleavage by NS1-nuc was also identified.

APA, Harvard, Vancouver, ISO, and other styles

10

Danober, Pascal Masutti Jean-Pierre. "Découverte d'un cas de sphérocytose héréditaire au décours d'une infection à Parvovirus B19 chez l'enfant à propos d'une observation /." [S.l] : [s.n], 2004. http://www.scd.uhp-nancy.fr/docnum/SCDMED_T_2004_DANOBER_PASCAL.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Human Parvovirus B19"

1

Elsacker-Niele, Anne-Marie van. Human parvovirus B19: Clinical consequences of infection. [Leiden: University of Leiden, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zaki, Maysaa El Sayed. Parvovirus B19 and hematological disordersin [sic] children. New York: Nova Science Publishers, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Parvovirus B19 and hematological disorders in children. Hauppauge, N.Y: Nova Science Publishers, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

J, Anderson Larry, and Young Neal S, eds. Human parvovirus B19. Basel: Karger, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Anderson, J. L., and N. S. Young, eds. Human Parvovirus B19. S. Karger AG, 1997. http://dx.doi.org/10.1159/isbn.978-3-318-00214-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zaki, Maysaa El Sayed. Parvovirus B19 and Hematological Disorders in Children. Nova Science Publishers, Incorporated, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Barton, S. A. Detection of parvovirus B19 in human sera by immune electron microscopy. 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Purandare, Amol, and Barbara A. Jantausch. Parvovirus. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190604813.003.0012.

Full text

Abstract:

Parvovirus B19 is a common infection in humans that occurs worldwide. Parvovirus B19 is transmitted through exposure to respiratory droplets, blood, and blood products, and through mother-to-child transmission (MTCT) in utero. Intrauterine parvovirus B19 infection is a rare occurrence during pregnancy but can result in significant morbidity and mortality for the fetus, including severe fetal anemia and nonimmune fetal hydrops (NIFH). Intrauterine transfusion can be successful in treating fetal anemia. Neurodevelopmental impairment has been reported in infants with congenital infection who have received intrauterine transfusion (IUT). Future research on the development of antiviral agents for the treatment of parvovirus B19 infection in pregnant women is needed, along with the development of a parvovirus B19 vaccine. Longitudinal studies to evaluate neurodevelopmental outcome of infants with a history of congenital parvovirus B19 infection are needed in order to facilitate the optimal evaluation and management of these infants.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Human Parvovirus B19"

1

Coia, John, and Heather Cubie. "Human parvovirus B19." In The Immunoassay Kit Directory, 798–808. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-009-0359-3_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Erdman, D. D. "Human Parvovirus B19: Laboratory Diagnosis." In Monographs in Virology, 93–104. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000061678.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Anderson, L. J., and N. S. Young. "Human Parvovirus B19 (Preliminary Pages)." In Monographs in Virology, 0. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000061682.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fridell, Eva, Alexander Blinkovski, Mattias Mannervik, Ulla Rudén, Britta Wahren, and Jerzy Trojnar. "Peptides from human parvovirus B19." In Peptides 1990, 905–7. Dordrecht: Springer Netherlands, 1991. http://dx.doi.org/10.1007/978-94-011-3034-9_371.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Agbandje-McKenna, M., and M. G. Rossmann. "The Structure of Human Parvovirus B19." In Monographs in Virology, 3–15. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000061674.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Brown, K. E., and N. S. Young. "Human Parvovirus B19: Pathogenesis of Disease." In Monographs in Virology, 105–19. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000061679.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Brown, K. E. "Human Parvovirus B19 Epidemiology and Clinical Manifestations." In Monographs in Virology, 42–60. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000061676.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Anderson, L. J. "Treatment and Prevention of Human Parvovirus B19 Disease." In Monographs in Virology, 137–48. Basel: KARGER, 1997. http://dx.doi.org/10.1159/000061681.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Clewley, Jonathan P. "Polymerase Chain Reaction Diagnosis of Human Parvovirus B19." In Diagnosis of Human Viruses by Polymerase Chain Reaction Technology, 285–96. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-84766-0_22.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Tovo, Pier-Angelo, Stefania Bezzio, and Clara Gabiano. "Fetal infections: Rubella, HIV, HCV, HBV, and Human Parvovirus B19." In Neonatology, 880–92. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-1405-3_113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Human Parvovirus B19"

1

Román-Ivorra, JA, C. Fernández-Carballido, JJ Alegre-Sancho, C. Martínez, and L. Abad. "OP0107 Human parvovirus b19 infection associated arthritis: clinical findings." In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.719.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Garcia, RCN Cubel, KML Azevedo, S. Setubal, MM Siqueira, and Oliveira AS. "P3.192 Human parvovirus b19 among brazilian patients infected with hiv." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.427.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Li, Yasha, Yanming Dong, Guopeng Xu, Peng Xu, Dan Zhao, Pengying Yue, Ying Wang, Kaiyu Liu, and Yi Li. "Notice of Retraction: The High Risk of Human Parvovirus B19 Infection in Patients with Malignant Tumors." In 2011 5th International Conference on Bioinformatics and Biomedical Engineering. IEEE, 2011. http://dx.doi.org/10.1109/icbbe.2011.5781530.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Deng, Xuefeng, Yanming Dong, Yunyun Zhu, Dan Zhao, Xinyan Jian, Zhihong Feng, Zhongchao Gai, Kaiyu Liu, and Yi Li. "Notice of Retraction: Evidence of the Human Parvovirus B19 Circulating in Childbearing-Age Women in Wuhan of Hubei Province." In 2011 5th International Conference on Bioinformatics and Biomedical Engineering. IEEE, 2011. http://dx.doi.org/10.1109/icbbe.2011.5780411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!